ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Jia Ruan Discusses Lenalidomide Plus Rituximab in MCL

Jia Ruan, MD, PhD
Published: Tuesday, Dec 09, 2014



Jia Ruan, MD, PhD, is an associate professor at Weill Cornell Medical College, discusses sustained remissions experienced by patients treated with the combination of lenalidomide and rituximab as initial treatment for mantle cell lymphoma (MCL).

This is the first phase II study to explore the combination of rituximab and lenalidomide, Ruan notes. The study enrolled 38 patients with MCL, of which 84.2% responded to therapy. The complete remission rate with the combination was 52.6%.

The median progression-free survival was not reached after an average of 2 years on therapy. These findings are remarkable, Ruan states, and demonstrated a meaningful response rate and duration.

<<< View more from the 2014 ASH Annual Meeting



Jia Ruan, MD, PhD, is an associate professor at Weill Cornell Medical College, discusses sustained remissions experienced by patients treated with the combination of lenalidomide and rituximab as initial treatment for mantle cell lymphoma (MCL).

This is the first phase II study to explore the combination of rituximab and lenalidomide, Ruan notes. The study enrolled 38 patients with MCL, of which 84.2% responded to therapy. The complete remission rate with the combination was 52.6%.

The median progression-free survival was not reached after an average of 2 years on therapy. These findings are remarkable, Ruan states, and demonstrated a meaningful response rate and duration.

<<< View more from the 2014 ASH Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x